Subtype
Malignant Male Reproductive System Neoplasm
CI-CAN-00003180Explore in graph →
1,451 active trials27 approved drugs58 evidence items
- NCIt
- C8561
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003180Explore in graph →
Clinical trials
6,227 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (762)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00861471 | Docetaxel (Taxotere) and Imatinib Mesylate (Gleevec) in Hormone Refractory Prostate Cancer | terminated | Phase 1 / Phase 2 | 24 | NYU Langone HealthOTHER | 1 | Jun 30, 2016 | clinicaltrials |
| NCT02816840 | PET-CT/MRI in the Radiotherapy for Prostate Cancer | unknown | Phase 1 / Phase 2 | 90 | Xuzhou Medical UniversityOTHER | 0 | Jun 29, 2016 | clinicaltrials |
| Docetaxel With or Without Low-dose, Short Course Sunitinib in Refractory Solid Tumors |
| unknown |
| Phase 2 |
| 80 |
| National University Hospital, SingaporeOTHER |
| 1 |
| Jun 22, 2016 |
| clinicaltrials |
| NCT00562315 | FACBC PET/CT for Recurrent Prostate Cancer | completed | Phase 2 | 128 | David M. Schuster, MDOTHER | 1 | Jun 21, 2016 | clinicaltrials |
| NCT02140138 | An Open Label Randomised Trial of RNActive® Cancer Vaccine in High Risk and Intermediate Risk Patients With Prostate Cancer | terminated | Phase 2 | 35 | CureVacINDUSTRY | 1 | Jun 13, 2016 | clinicaltrials |
| NCT01658527 | TAK-700 in Castration Resistant Prostate Cancer | withdrawn | Phase 2 | 0 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 1 | Jun 10, 2016 | clinicaltrials |
| NCT00503984 | A Phase I/II Study of Azacitidine, Docetaxel, and Prednisone for Metastatic Prostate Cancer Patients | terminated | Phase 1 / Phase 2 | 22 | University of MiamiOTHER | 1 | Jun 9, 2016 | clinicaltrials |
| NCT01549951 | Study to Investigate the Effects of Orteronel on the QT/QTc Interval in Patients With Metastatic Castration-Resistant Prostate Cancer | completed | Phase 2 | 50 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Jun 1, 2016 | clinicaltrials |
| NCT00985738 | Role of Dutasteride in Patients Undergoing 3D Mapping Biopsy in Early Stage Prostate Cancer | terminated | Phase 2 | 16 | University of Colorado, DenverOTHER | 1 | May 17, 2016 | clinicaltrials |
| NCT00321646 | Neoadjuvant Bevacizumab Plus Docetaxel in High Risk Patients With Prostate Cancer Undergoing Radical Prostatectomy | completed | Phase 2 | 42 | Mary-Ellen Taplin, MDOTHER | 1 | May 16, 2016 | clinicaltrials |
| NCT00459186 | The Use of RAD001 With Docetaxel in the Treatment of Metastatic, Androgen Independent Prostate Cancer | completed | Phase 1 / Phase 2 | 19 | Dana-Farber Cancer InstituteOTHER | 1 | May 16, 2016 | clinicaltrials |
| NCT02423889 | Stereotactic Volumetric Radiotherapy in Prostate Cancer | completed | Phase 2 | 28 | IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, ItalyOTHER | 1 | May 11, 2016 | clinicaltrials |
| NCT00121238 | Cilengitide in Treating Patients With Prostate Cancer | completed | Phase 2 | 16 | National Cancer Institute (NCI)NIH | 1 | Apr 28, 2016 | clinicaltrials |
| NCT01981707 | F-choline PET in Early Response Assessment for Castration Resistant Prostatic Cancer(PRECHOL) | terminated | Phase 2 / Phase 3 | 12 | University Hospital, GrenobleOTHER | 1 | Apr 28, 2016 | clinicaltrials |
| NCT02484339 | Treatment of Advanced Castration Resistant Prostate Carcinoma With Limited Bone Metastases (α-RT)(α-RT) | unknown | Phase 2 | 274 | University Hospital FreiburgOTHER | 1 | Apr 27, 2016 | clinicaltrials |
| NCT00707356 | Study of WST11 in Patients With Localized Prostate Cancer | completed | Phase 2 | 42 | Steba Biotech S.A.OTHER | 3 | Apr 19, 2016 | clinicaltrials |
| NCT00345293 | Dendritic Cell Vaccine Study (DC/PC3) for Prostate Cancer | completed | Phase 1 / Phase 2 | 13 | Rockefeller UniversityOTHER | 1 | Apr 18, 2016 | clinicaltrials |
| NCT01812746 | A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Administered to Patients With Metastatic Castration-Resistant Prostate Cancer | completed | Phase 2 | 42 | BIND TherapeuticsINDUSTRY | 1 | Apr 15, 2016 | clinicaltrials |
| NCT01046916 | Safety and Efficacy Study of TAK-700 in Patients With Nonmetastatic Castration-resistant Prostate Cancer and a Rising Prostate-specific Antigen | completed | Phase 2 | 38 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Apr 4, 2016 | clinicaltrials |
| NCT00203424 | Treatment of Prostate Cancer With Adjuvant Bevacizumab Plus Erlotinib | completed | Phase 2 | 23 | Translational Oncology Research InternationalOTHER | 1 | Mar 25, 2016 | clinicaltrials |
| NCT00583492 | Randomized Trial of Suicide Gene Therapy and Prostate Cancer(ReCAP) | completed | Phase 2 | 44 | Henry Ford Health SystemOTHER | 1 | Mar 17, 2016 | clinicaltrials |
| NCT01603420 | External Beam Radiation With or Without Chemotherapy to Treat High Risk Prostate Cancer | terminated | Phase 2 / Phase 3 | 2 | Proton Collaborative GroupNETWORK | 1 | Mar 14, 2016 | clinicaltrials |
| NCT02341404 | A Study of 2-hydroxyflutamide (Liproca Depot), Injected Into the Prostate in Patients With Localized Prostate Cancer | completed | Phase 2 | 23 | Lidds ABINDUSTRY | 2 | Mar 11, 2016 | clinicaltrials |
| NCT00438464 | Finasteride in Treating Patients With Stage II Prostate Cancer Who Are Undergoing Surgery | completed | Phase 2 | 204 | National Cancer Institute (NCI)NIH | 1 | Mar 9, 2016 | clinicaltrials |
| NCT02014831 | Efficacy and Safety of Cetuximab in Metastatic Penile Carcinoma (PENILANE)(PENILANE) | withdrawn | Phase 2 | 0 | Centre Leon BerardOTHER | 1 | Feb 25, 2016 | clinicaltrials |
| NCT00587964 | Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases | completed | Phase 2 | 51 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 22, 2016 | clinicaltrials |
| NCT02035124 | Cabazitaxel and BKM120 in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel | withdrawn | Phase 2 | 0 | SCRI Development Innovations, LLCOTHER | 1 | Feb 11, 2016 | clinicaltrials |
| NCT00454571 | Pazopanib Hydrochloride After Leuprolide Acetate or Goserelin Acetate in Treating Patients With Relapsed Prostate Cancer | completed | Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | Feb 10, 2016 | clinicaltrials |
| NCT00085566 | Everolimus and Gefitinib in Treating Patients With Progressive Glioblastoma Multiforme or Progressive Metastatic Prostate Cancer | completed | Phase 1 / Phase 2 | 61 | Memorial Sloan Kettering Cancer CenterOTHER | 2 | Jan 20, 2016 | clinicaltrials |
| NCT00124566 | Study of Irofulven in Patients With Hormone-refractory Prostate Cancer | completed | Phase 2 | 135 | Eisai Inc.INDUSTRY | 9 | Jan 18, 2016 | clinicaltrials |
| NCT02643511 | Hemiablative Focal Brachytherapy Pilot Study | unknown | Phase 2 | 20 | St George Hospital, AustraliaOTHER | 1 | Dec 31, 2015 | clinicaltrials |
| NCT00734851 | Multimodality Phase II Study in Prostate Cancer | terminated | Phase 2 | 36 | Duke UniversityOTHER | 1 | Dec 23, 2015 | clinicaltrials |
| NCT01674270 | Degarelix Neo-Adjuvant Radical Prostatectomy Trial | completed | Phase 2 | 35 | University Health Network, TorontoOTHER | 1 | Dec 22, 2015 | clinicaltrials |
| NCT01477749 | Sipuleucel-T Manufacturing Demonstration Study | completed | Phase 2 | 47 | DendreonINDUSTRY | 4 | Dec 9, 2015 | clinicaltrials |
| NCT00932672 | Atkins Diet and Prostate Cancer Clinical Trial | terminated | Phase 2 | 45 | Duke UniversityOTHER | 1 | Dec 7, 2015 | clinicaltrials |
| NCT00020735 | Toremifene Followed by Radical Prostatectomy in Treating Patients With Stage I or Stage II Prostate Cancer | completed | Phase 2 | 45 | Joel Nelson, MDOTHER | 1 | Dec 2, 2015 | clinicaltrials |
| NCT00110188 | Ridaforolimus (AP23573/MK-8669) in Participants With Taxane-Resistant Androgen-Independent Prostate Cancer (AIPC)(MK-8669-017) | completed | Phase 2 | 39 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Nov 20, 2015 | clinicaltrials |
| NCT00741039 | Prospective Trial of Vaccine Responses Against Pneumococcus and Influenza in Adult Cancer Patients 65 Years of Age and Older | completed | Phase 2 | 126 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 20, 2015 | clinicaltrials |
| NCT00928174 | Measurement of Anti-Androgen Response Using Fluorine-18 Fluorocholine PET/CT in Androgen-Insensitive Prostate Cancer | completed | Phase 1 / Phase 2 | 27 | Queen's Medical CenterOTHER | 1 | Nov 11, 2015 | clinicaltrials |
| NCT01898065 | Evaluation of Hypoxia by PET With F-Miso in Radiation Therapy of Prostate Cancer(HYPOXProstat) | completed | Phase 2 | 20 | Institut Cancerologie de l'OuestOTHER | 1 | Nov 9, 2015 | clinicaltrials |
| NCT01795703 | A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer Who Have Received Docetaxel | completed | Phase 2 | 47 | Janssen Research & Development, LLCINDUSTRY | 1 | Nov 4, 2015 | clinicaltrials |
| NCT00524680 | Vitamin D in Treating Patients With Prostate Cancer | completed | Phase 2 | 148 | Roswell Park Cancer InstituteOTHER | 1 | Nov 2, 2015 | clinicaltrials |
| NCT01541007 | A Study Looking at Novel Scheduling of Cabazitaxel for Patients With Metastatic Prostate Cancer(ConCab) | completed | Phase 2 | 100 | Jeffrey Yachnin M.D., PhD.OTHER | 1 | Nov 2, 2015 | clinicaltrials |
| NCT00853697 | Exogenous Testosterone Plus Dutasteride for the Treatment of Castrate Metastatic Prostate Cancer | completed | Phase 2 | 6 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 30, 2015 | clinicaltrials |
| NCT00560482 | Efficacy Study of ABR-215050 to Treat Prostate Cancer | completed | Phase 2 | 206 | Active Biotech ABINDUSTRY | 3 | Oct 26, 2015 | clinicaltrials |
| NCT02042885 | A Clinical Trial to Determine the Most Suitable Dose of OPB-111001 in Patients With Advanced Cancer | terminated | Phase 1 / Phase 2 | 79 | Otsuka Novel Products GmbHINDUSTRY | 1 | Oct 20, 2015 | clinicaltrials |
| NCT01530984 | Ipilimumab and GMCSF Immunotherapy for Prostate Cancer | withdrawn | Phase 2 | 0 | Lawrence FongOTHER | 1 | Oct 5, 2015 | clinicaltrials |
| NCT00585416 | Study of CGC-11047 in Patients With Metastatic Hormone Refractory Prostate Cancer | terminated | Phase 2 | 23 | University of Wisconsin, MadisonOTHER | 1 | Oct 2, 2015 | clinicaltrials |
| NCT02480010 | A Study of Pertuzumab in Participants With Prostate Cancer | terminated | Phase 2 | 68 | Hoffmann-La RocheINDUSTRY | 6 | Sep 18, 2015 | clinicaltrials |
| NCT00818480 | An Extension Study Administering YM155 to Subjects Previously Enrolled in Another Protocol Administering YM155 | completed | Phase 2 | 10 | Astellas Pharma IncINDUSTRY | 1 | Sep 4, 2015 | clinicaltrials |
Data updated 24 days agoSource updated Jun 30, 2016source: clinicaltrials